Table 2.

HIF inhibitors currently in clinical trials

Agent	Target	Phase/status
AFP464	AhR	I, R
Carboxyamido-triazole	CCB in VEGF	I, II, ANR, C
SU5416	c-MET	I, ANR, C
Alvocidib (flavopiridol)	Cyclin-dependent kinase	II, C
Decitabine	Cytosine nucleoside/DNMT	I, ANR, C, #
XL-647	EGFR	I, C
Lonafarnib	Farnesyl-OH-transferase	II, C
Valproic acid	HDAC	I, C, R, #
MS-275	HDAC	I, C
Belinostat	HDAC	I, C, R, #
Tributyrin	HDAC	I, C
Trastuzumab	Her2/neu	I, C, #
Vandetanib	Her2/neu; EGFR	I, II, ANR, C, R
Romidepsin (FK228)	Histone deacetylase	II, C, #
Vorinostat (SAHA)	Histone deacetylase	I, R, #
Panobinostat (LBH589)	Histone deacetylase	I, R, #
Tanespimycin	HSP	I, II, ANR, C, EBI, NYR
Taxoprexin	Microtubule	II, C
Docetaxel	Microtubule	II, C, T, #
Ixabepilone	Microtubule	I, II, C, #
Patupilone	Microtubule	II, C
XL-765	mTOR	I, R
Temsirolimus	mTOR	I, II, NYR, R, #
Everolimus	mTOR	I, II, III, R, #
Pazopanib	Multitarget TKI	I, R, #
Imatinib	PDGFR; cKIT	I, II, ANR, C, T, #
Bortezomib	Proteasome	I, II, ANR, C, #
EZN-2968	RNA	I, R,
PX-12	Thioredoxin	I, II, C
Topotecan	Topoisomerase	I, II, ALL, #
Vatalanib	VEGF	I, II, ANR, C, R

Phase I–III status: ANR active not recruiting, C completed, EBI enrollment by invitation, NYR not yet recruited, R recruiting, T terminated, # FDA approved